Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
2 African trypanosomiasis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
3 African trypanosomiasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
4 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 AGE-RAGE signaling pathway in diabetic complications 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
6 Alcoholic liver disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
7 Allograft rejection 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
8 Alzheimer disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 Alzheimer disease 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
10 Amoebiasis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
11 Amoebiasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
12 Amoebiasis 💬
2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
13 Amphetamine addiction 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
14 Amyotrophic lateral sclerosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
15 Antigen processing and presentation 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
16 Axon guidance 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
17 B cell receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
18 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
19 C-type lectin receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
20 Calcium signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
21 Cellular senescence 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
22 cGMP-PKG signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
23 Chagas disease 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
24 Chagas disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
25 Chemical carcinogenesis - receptor activation 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
26 Chemokine signaling pathway 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
27 Cholinergic synapse 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
28 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
29 Coronavirus disease - COVID-19 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
30 Coronavirus disease - COVID-19 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
31 Cytokine-cytokine receptor interaction 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
32 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
33 Cytokine-cytokine receptor interaction 💬
2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
34 Cytokine-cytokine receptor interaction 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
35 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
36 Dopaminergic synapse 💬
3件: PPP3C, PPP3C, PPP3C 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 Efferocytosis 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
38 Epstein-Barr virus infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
39 Fluid shear stress and atherosclerosis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
40 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
41 Fluid shear stress and atherosclerosis 💬
2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
42 Folate biosynthesis 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
43 Folate biosynthesis 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
44 Folate transport and metabolism 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
45 Folate transport and metabolism 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
46 Glucagon signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
47 Glutamatergic synapse 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
48 Graft-versus-host disease 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
49 Graft-versus-host disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
50 Growth hormone synthesis, secretion and action 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
51 Hematopoietic cell lineage 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
52 Hematopoietic cell lineage 💬
2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
53 Hematopoietic cell lineage 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
54 Hepatitis B 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
55 Hepatitis C 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
56 Hepatitis C 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
57 Herpes simplex virus 1 infection 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
58 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 Herpes simplex virus 1 infection 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
60 HIF-1 signaling pathway 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
61 HIF-1 signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
62 Hormone signaling 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
63 Human cytomegalovirus infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
64 Human cytomegalovirus infection 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
65 Human cytomegalovirus infection 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
66 Human cytomegalovirus infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
67 Human cytomegalovirus infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
68 Human immunodeficiency virus 1 infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
69 Human papillomavirus infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
70 Human T-cell leukemia virus 1 infection 💬
2件: IL1R1, IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
71 Human T-cell leukemia virus 1 infection 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
72 Human T-cell leukemia virus 1 infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
73 IL-17 signaling pathway 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
74 IL-17 signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
75 Inflammatory bowel disease 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
76 Inflammatory bowel disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
77 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
78 Inflammatory mediator regulation of TRP channels 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
79 Influenza A 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
80 Influenza A 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
81 Influenza A 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
82 JAK-STAT signaling pathway 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
83 JAK-STAT signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
84 JAK-STAT signaling pathway 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
85 Kaposi sarcoma-associated herpesvirus infection 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
86 Kaposi sarcoma-associated herpesvirus infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
87 Legionellosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
88 Leishmaniasis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
89 Leishmaniasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
90 Leishmaniasis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
91 Lipid and atherosclerosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
92 Lipid and atherosclerosis 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
93 Lipid and atherosclerosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
94 Long-term potentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
95 Malaria 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
96 Malaria 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
97 MAPK signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
98 MAPK signaling pathway 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
99 MAPK signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
100 Measles 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
101 Measles 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
102 Natural killer cell mediated cytotoxicity 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
103 Natural killer cell mediated cytotoxicity 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
104 Necroptosis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
105 Necroptosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
106 Necroptosis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
107 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisolone 💬 Prednisolone 41件:  3 , 11, 13, 14, 18, 25, 26, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 60, 61, 63, 64, 66, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 251, 269, 271, 296, 299, 300 💬
108 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
109 NF-kappa B signaling pathway 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
110 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
111 NOD-like receptor signaling pathway 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
112 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
113 Non-alcoholic fatty liver disease 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
114 One carbon pool by folate 💬
2件: DHFR, DHFR 💬 Methotrexate 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
115 One carbon pool by folate 💬
2件: DHFR, DHFR 💬 Methotrexate sodium 💬 Methotrexate 39件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 54, 55, 56, 60, 62, 65, 84, 85, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 284, 285, 286, 326, 331 💬
116 Oocyte meiosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
117 Osteoclast differentiation 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
118 Osteoclast differentiation 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
119 Osteoclast differentiation 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
120 Osteoclast differentiation 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
121 Osteoclast differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
122 Oxytocin signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
123 Pancreatic cancer 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
124 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
125 Pathogenic Escherichia coli infection 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
126 Pathways in cancer 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
127 Pathways in cancer 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
128 Pathways in cancer 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
129 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
130 Pathways of neurodegeneration - multiple diseases 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
131 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
132 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
133 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
134 Pertussis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
135 PI3K-Akt signaling pathway 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
136 PI3K-Akt signaling pathway 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
137 Prion disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
138 Prion disease 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
139 Prolactin signaling pathway 💬
1件: JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
140 Prostate cancer 💬
1件: IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
141 Proteasome 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
142 Pyrimidine metabolism 💬
1件: DHODH 💬 Leflunomide 💬 Leflunomide 13件: 11, 40, 46, 49, 53, 54, 66, 107, 162, 224, 270, 271, 300 💬
143 Renin secretion 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
144 Rheumatoid arthritis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
145 Rheumatoid arthritis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
146 Salmonella infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
147 Shigellosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
148 Shigellosis 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
149 Signaling pathways regulating pluripotency of stem cells 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
150 Systemic lupus erythematosus 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
151 T cell receptor signaling pathway 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
152 T cell receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
153 TGF-beta signaling pathway 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
154 Th1 and Th2 cell differentiation 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
155 Th1 and Th2 cell differentiation 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
156 Th1 and Th2 cell differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
157 Th17 cell differentiation 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
158 Th17 cell differentiation 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
159 Th17 cell differentiation 💬
1件: IL1R1 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
160 Th17 cell differentiation 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
161 Th17 cell differentiation 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
162 Th17 cell differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
163 TNF signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
164 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
165 Toll-like receptor signaling pathway 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
166 Toxoplasmosis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
167 Toxoplasmosis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
168 Transcriptional misregulation in cancer 💬
1件: IL1R2 💬 Anakinra 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 54, 56, 84, 86, 97, 106, 107, 266, 299 💬
169 Tuberculosis 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
170 Tuberculosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
171 Tuberculosis 💬
2件: JAK1, JAK2 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
172 Tuberculosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
173 Type I diabetes mellitus 💬
1件: IFNG 💬 Emapalumab 💬 Emapalumab 5件: 49, 54, 60, 65, 107 💬
174 Type I diabetes mellitus 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
175 VEGF signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
176 Viral carcinogenesis 💬
1件: JAK1 💬 Baricitinib 💬 Baricitinib 21件:  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
177 Viral protein interaction with cytokine and cytokine receptor 💬
1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 24件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 149, 153, 266, 271, 298, 331 💬
178 Wnt signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Cyclosporine 💬 Cyclosporine 42件: 11, 19, 20, 26, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
179 Yersinia infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬